GRAIL, Inc. Common Stock GRAL

GRAIL Inc. es una empresa de atención médica. La empresa se enfoca en desarrollar nuevas tecnologías para la detección temprana del cáncer. La prueba Galleri de la empresa es una prueba de detección temprana de múltiples cánceres (MCED) que puede ayudar a detectar muchos de los cánceres que no tienen una detección recomendada. La prueba Galleri busca una señal compartida por varios cánceres que de otra manera pasarían desapercibidos. Si se detecta una señal de cáncer, Galleri predice el tipo de tejido u órgano asociado con la señal de cáncer. Si se detecta una señal de cáncer, Galleri predice el tipo de tejido u órgano asociado con la señal de cáncer para ayudar a guiar pruebas diagnósticas de seguimiento que pueden incluir análisis de laboratorio o imágenes para confirmar el cáncer. La prueba Galleri busca ácido desoxirribonucleico (ADN) libre de células y identifica si proviene de células sanas o cancerosas. Sus pruebas de detección temprana de múltiples cánceres (MCED) analizan el ADN que ha sido liberado al torrente sanguíneo por todas las células que crecen en el cuerpo, incluidas las células cancerosas.

• The Motley Fool 30 sept

  3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

  Grail, spun off from Illumina in 2024, develops the Galleri blood test for early cancer detection. The company has grown revenue from $93M (2023) to $147M (2025) through cash-only sales and is expected to reach $181M in 2026. An FDA panel recently endorsed premarket approval with three affirmative votes, potentially supporting FDA approval by 2027. Despite trading at 21x 2028 sales, analysts believe the stock could be undervalued if FDA approval comes early and adoption accelerates.

  

• GlobeNewswire Inc. 3 ago

  PICS FINAL DEADLINE ALERT: PicS N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before August 4, 2026 Deadline – Hagens Berman

  A securities class action lawsuit has been filed against PicS N.V. (NASDAQ: PICS) alleging the company made materially false and misleading statements in its January 2026 IPO by failing to disclose internal findings of deficient credit evaluation policies discovered in December 2025. The lawsuit claims these omissions masked severe portfolio deterioration, heightened default risks, and increased non-performing loans. Post-IPO disclosures revealed R$590 million in loan reclassifications and a doubled default formation rate, causing the stock to plummet over 50% from its $19.00 IPO price to under $9.00. The lead plaintiff deadline is August 4, 2026.

  

• GlobeNewswire Inc. 3 ago

  GRAL FINAL DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline

  Hagens Berman has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging the company misled investors about its NHS-Galleri cancer screening trial's design and efficacy. GRAIL failed to meet the trial's primary endpoint on February 19, 2026, causing the stock to plummet 50.55% and erasing $2.2 billion in market capitalization. The lead plaintiff deadline is August 4, 2026.

  

• GlobeNewswire Inc. 1 ago

  ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH

  Rosen Law Firm has filed class action lawsuits against Park Ha Biological Technology Co., Ltd. (PHH, BYAH) for securities fraud involving false statements and undisclosed fraudulent stock promotion schemes during December 2024-July 2025. A separate lawsuit targets GRAIL, Inc. (GRAL) with an August 4, 2026 deadline for investors to secure counsel. Both cases allege material misstatements and failure to disclose adverse facts affecting stock prices.

  

• The Motley Fool 1 ago

  Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?

  Grail's stock has declined from a record high of $116.06 to under $70 following a failed NHS England trial for its Galleri blood cancer test. However, the company continues generating revenue ($147M in 2025) through direct-to-consumer sales and is expected to grow to $281M by 2028. Despite the setback, analysts recommend holding the stock as an FDA approval could significantly boost growth prospects.